Welcome to the Oncomine Blog
-
Advancements in Liquid Biopsy NGS for Precision Oncology
How can we enhance the clinical utility and accessibility of liquid biopsy NGS? Liquid biopsy next-g... -
Revolutionizing Cancer Treatment Selection with Next-Generation Sequencing
Introduction In a recent interview with the Anatomical and Molecular Pathology Lab at Sydpath, St. V... -
Performing an analytical validation for a next-generation sequencing workflow: A Q&A session with Liverpool Clinical Laboratories
Recently, Thermo Fisher Scientific sat down with Carolina Felix, Senior Biomedical Scientist at the ... -
When a rare cancer lab experienced unexpected NGS results, a Thermo Fisher Scientific TAS solved the puzzle
Some NGS runs on Dr. Gabriella Gamberi’s Ion GeneStudio S5 System had a high number of low-quality r... -
Announcing the Latest Oncomine Clinical Research Grant Awardees Advancing Precision Medicine in Oncology
Thermo Fisher Scientific has announced the recipients of the latest Oncomine Clinical Research Grant... -
Recommendations for Equitable and Widespread Implementation of Liquid Biopsy in Cancer Care
A recently published article by the BLOODPAC Consortium details the potential of liquid biopsy in th... -
Q&A with Integra Connect: When Waiting to Treat Leads to Better Outcomes
Precision medicine is on the rise. However, these groundbreaking, targeted therapies for hard-to-tre... -
Healthcare Economic Analysis Makes Case for In-house NGS
Next-generation sequencing (NGS) has become an increasingly important tool for identifying molecular... -
Clinical Utility of Frontline NGS for Myeloid Malignancies
In his recent talk at OncomineWorld 2023, Dr. Bekim Sadikovic presented a strong, evidence-based arg...